The Royal College of Ophthalmologists has published updated guidelines for the monitoring of hydroxychloroquine retinopathy. The new guide requires a service led by consultants. The CGC is working to bring a service to operation in Devon and will establish an updated shared care directive as soon as the service is implemented. This guidance covers the use of hydroxychloroquine in the treatment of patients with rheumatic diseases, in particular lupus erythematosus and rheumatoid arthritis coronavirus (COVID-19): in order to minimise the need for patients to visit personal contact centres with the NHS, the monitoring of the safety of medicinal products for hydroxychloroquine has been temporarily suspended. These amendments are set out in blue in the attached updated Directive. For patients receiving treatment in combination with other DMARDs, refer to the recommendations for the other DMARD for transitional recommendations on surveillance during the COVID-19 pandemic. For all patients, if they are uncomfortable for any reason, they should talk to their family doctor. Patients who have been taking 200 mg twice a day for more than 10 years should contact their specialist for advice. Form letters are available to support practices in writing to their patients affected by these temporary changes. . .